|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sher T, Dy GK and Adjei AA: Small cell
lung cancer. Mayo Clin Proc. 83:355–367. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Argilés JM, Busquets S, Stemmler B and
López-Soriano FJ: Cancer cachexia: Understanding the molecular
basis. Nat Rev Cancer. 14:754–762. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ross PJ, Ashley S, Norton A, Priest K,
Waters JS, Eisen T, Smith IE and O'Brien ME: Do patients with
weight loss have a worse outcome when undergoing chemotherapy for
lung cancers? Br J Cancer. 90:1905–1911. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fearon KC, Voss AC and Hustead DS; Cancer
Cachexia Study Group, : Definition of cancer cachexia: Effect of
weight loss, reduced food intake, and systemic inflammation on
functional status and prognosis. Am J Clin Nutr. 83:1345–1350.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Fearon K, Strasser F, Anker SD, Bosaeus I,
Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N,
Mantovani G, et al: Definition and classification of cancer
cachexia: An international consensus. Lancet Oncol. 12:489–495.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Arends J, Strasser F, Gonella S, Solheim
TS, Madeddu C, Ravasco P, Buonaccorso L, de van der Schueren MAE,
Baldwin C, Chasen M, et al: Cancer cachexia in adult patients: ESMO
clinical practice guidelines. ESMO Open. 6:1000922021. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Roeland EJ, Bohlke K, Baracos VE, Bruera
E, Del Fabbro E, Dixon S, Fallon M, Herrstedt J, Lau H, Platek M,
et al: Management of cancer cachexia: ASCO guideline. J Clin Oncol.
38:2438–2453. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang H and Garcia JM: Anamorelin
hydrochloride for the treatment of cancer-anorexia-cachexia in
NSCLC. Expert Opin Pharmacother. 16:1245–1253. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Currow DC and Abernethy AP: Anamorelin
hydrochloride in the treatment of cancer anorexia-cachexia
syndrome. Future Oncol. 10:789–802. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pietra C, Takeda Y, Tazawa-Ogata N, Minami
M, Yuanfeng X, Duus EM and Northrup R: Anamorelin HCl (ONO-7643), a
novel ghrelin receptor agonist, for the treatment of cancer
anorexia-cachexia syndrome: Preclinical profile. J Cachexia
Sarcopenia Muscle. 5:329–337. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Delporte C: Structure and physiological
actions of ghrelin. Scientifica. 2013:5189092013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kojima M, Hosoda H, Date Y, Nakazato M,
Matsuo H and Kangawa K: Ghrelin is a growth-hormone-releasing
acylated peptide from stomach. Nature. 402:656–660. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Neary NM, Small CJ, Wren AM, Lee JL, Druce
MR, Palmieri C, Frost GS, Ghatei MA, Coombes RC and Bloom SR:
Ghrelin increases energy intake in cancer patients with impaired
appetite: Acute, randomized, placebo-controlled trial. J Clin
Endocrinol Metab. 89:2832–2836. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wren AM, Seal LJ, Cohen MA, Brynes AE,
Frost GS, Murphy KG, Dhillo WS, Ghatei MA and Bloom SR: Ghrelin
enhances appetite and increases food intake in humans. J Clin
Endocrinol Metab. 86:59922001. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Garcia JM, Friend J and Allen S:
Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic,
in patients with cancer-related cachexia: A multicenter,
randomized, double-blind, crossover, pilot study. Support Care
Cancer. 21:129–137. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Garcia JM and Polvino WJ: Effect on body
weight and safety of RC-1291, a novel, orally available ghrelin
mimetic and growth hormone secretagogue: Results of a phase I,
randomized, placebo-controlled, multiple-dose study in healthy
volunteers. Oncologist. 12:594–600. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Garcia JM and Polvino WJ: Pharmacodynamic
hormonal effects of anamorelin, a novel oral ghrelin mimetic and
growth hormone secretagogue in healthy volunteers. Growth Horm IGF
Res. 19:267–273. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Temel JS, Abernethy AP, Currow DC, Friend
J, Duus EM, Yan Y and Fearon KC: Anamorelin in patients with
non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2):
Results from two randomised, double-blind, phase 3 trials. Lancet
Oncol. 17:519–531. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Currow D, Temel JS, Abernethy A,
Milanowski J, Friend J and Fearon KC: ROMANA 3: A phase 3 safety
extension study of anamorelin in advanced non-small-cell lung
cancer (NSCLC) patients with cachexia. Ann Oncol. 28:1949–1956.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Takayama K, Katakami N, Yokoyama T, Atagi
S, Yoshimori K, Kagamu H, Saito H, Takiguchi Y, Aoe K, Koyama A, et
al: Anamorelin (ONO-7643) in Japanese patients with non-small cell
lung cancer and cachexia: Results of a randomized phase 2 trial.
Support Care Cancer. 24:3495–3505. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Katakami N, Uchino J, Yokoyama T, Naito T,
Kondo M, Yamada K, Kitajima H, Yoshimori K, Sato K, Saito H, et al:
Anamorelin (ONO-7643) for the treatment of patients with non-small
cell lung cancer and cachexia: Results from a randomized,
double-blind, placebo-controlled, multicenter study of Japanese
patients (ONO-7643-04). Cancer. 124:606–616. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hamauchi S, Furuse J, Takano T, Munemoto
Y, Furuya K, Baba H, Takeuchi M, Choda Y, Higashiguchi T, Naito T,
et al: A multicenter, open-label, single-arm study of anamorelin
(ONO-7643) in advanced gastrointestinal cancer patients with cancer
cachexia. Cancer. 125:4294–4302. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wakabayashi H, Arai H and Inui A: The
regulatory approval of anamorelin for treatment of cachexia in
patients with non-small cell lung cancer, gastric cancer,
pancreatic cancer, and colorectal cancer in Japan: Facts and
numbers. J Cachexia Sarcopenia Muscle. 12:14–16. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Goldstraw P, Chansky K, Crowley J, Porta
RR, Asamura H, Eberhardt WEE, Nicholson AG, Groome P, Mitchell A,
Bolejack V, et al: The IASLC lung cancer staging project: Proposals
for revision of the TNM stage groupings in the forthcoming (eighth)
edition of the TNM classification for lung cancer. J Thorac Oncol.
11:39–51. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Oken MM, Creech RH, Tormey DC, Horton J,
Davis TE, McFadden ET and Carbone PP: Toxicity and response
criteria of the eastern cooperative oncology group. Am J Clin
Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Freites-Martinez A, Santana N,
Arias-Santiago S and Viera A: [Using the common terminology
criteria for adverse events (CTCAE-version 5.0) to evaluate the
severity of adverse events of anticancer therapies]. Actas
Dermosifiliogr (Engl Ed). 112:90–92. 2021.(In English, Spanish).
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Takayama K, Takiguchi T, Komura N and
Naito T: Efficacy and safety of anamorelin in patients with cancer
cachexia: Post-hoc subgroup analyses of a placebo-controlled study.
Cancer Med. 12:2918–2928. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
da Rocha IMG, Marcadenti A, de Medeiros
GOC, Bezerra RA, Rego JFM, Gonzalez MC and Fayh APT: Affiliations
expand is cachexia associated with chemotherapy toxicities in
gastrointestinal cancer patients? A prospective study. J Cachexia
Sarcopenia Muscle. 10:445–454. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Fujii H, Makiyama A, Iihara H, Okumura N,
Yamamoto S, Imai T, Arakawa S, Kobayashi R, Tanaka Y, Yoshida K and
Suzuki A: Cancer cachexia reduces the efficacy of nivolumab
treatment in patients with advanced gastric cancer. Anticancer Res.
40:7067–7075. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Morimoto K, Uchino J, Yokoi T, Kijima T,
Goto Y, Nakao A, Hibino M, Takeda T, Yamaguchi H, Takumi C, et al:
Affiliations expand impact of cancer cachexia on the therapeutic
outcome of combined chemoimmunotherapy in patients with non-small
cell lung cancer: A retrospective study. Oncoimmunology.
10:19504112021. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Stene GB, Helbostad JL, Amundsen T,
Sørhaug S, Hjelde H, Kaasa S and Grønberg BH: Changes in skeletal
muscle mass during palliative chemotherapy in patients with
advanced lung cancer. Acta Oncol. 54:340–348. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Antoun S, Birdsell L, Sawyer MB, Venner P,
Escudier B and Baracos VE: Association of skeletal muscle wasting
with treatment with sorafenib in patients with advanced renal cell
carcinoma: Results from a placebo-controlled study. J Clin Oncol.
28:1054–1060. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Vanhoutte G, van de Wiel M, Wouters K,
Sels M, Bartolomeeussen L, De Keersmaecker S, Verschueren C, De
Vroey V, De Wilde A, Smits E, et al: Cachexia in cancer: What is in
the definition? BMJ Open Gastroenterol. 3:e0000972016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Solheim TS, Laird BJA, Balstad TR, Stene
GB, Bye A, Johns N, Pettersen CH, Fallon M, Fayers P, Fearon K and
Kaasa S: A randomized phase II feasibility trial of a multimodal
intervention for the management of cachexia in lung and pancreatic
cancer. J Cachexia Sarcopenia Muscle. 8:778–788. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Naito T, Mitsunaga S, Miura S, Tatematsu
N, Inano T, Mouri T, Tsuji T, Higashiguchi T, Inui A, Okayama T, et
al: Feasibility of early multimodal interventions for elderly
patients with advanced pancreatic and non-small-cell lung cancer. J
Cachexia Sarcopenia Muscle. 10:73–83. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Miura S, Naito T, Mitsunaga S, Omae K,
Mori K, Inano T, Yamaguchi T, Tatematsu N, Okayama T, Morikawa A,
et al: A randomized phase II study of nutritional and exercise
treatment for elderly patients with advanced non-small cell lung or
pancreatic cancer: The NEXTAC-TWO study protocol. BMC Cancer.
19:5282019. View Article : Google Scholar : PubMed/NCBI
|
